This phase IV protocol is designed to evaluate the safety, clinical tolerability and immunogenicity of the 2005-2006 formulation of three widely used conventional influenza vaccines in children aged 6 to 35 months
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
270
University of Tampere Medical School
Tampere, Finland
Seroprotection, GMR's and Seroconversion rate at day 0 and day 50 following vaccination.
Solicited Local and Systemic Reactions Within 6 Days Following Each Vaccination And Adverse Events Thought the Study.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.